Modality
Vaccine
MOA
IL-13i
Target
FXIa
Pathway
DDR
FTDRA
Development Pipeline
Preclinical
~Nov 2012
→ ~Feb 2014
Phase 1
~May 2014
→ ~Aug 2015
Phase 2
~Nov 2015
→ ~Feb 2017
Phase 3
May 2017
→ Dec 2029
Phase 3Current
NCT07345133
2,959 pts·FTD
2017-05→2029-12·Terminated
2,959 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-12-203.7y awayPh3 Readout· FTD
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Termina…
Catalysts
Ph3 Readout
2029-12-20 · 3.7y away
FTD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07345133 | Phase 3 | FTD | Terminated | 2959 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Rimaosocimab | Amgen | Preclinical | FXIa |